Compare MSC & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MSC | ABOS |
|---|---|---|
| Founded | 2000 | 1996 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 188.9M | 165.6M |
| IPO Year | 2017 | 2021 |
| Metric | MSC | ABOS |
|---|---|---|
| Price | $1.12 | $0.18 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 72.1K | ★ 5.6M |
| Earning Date | 11-04-2026 | 10-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.76 | $0.17 |
| 52 Week High | $4.19 | $3.60 |
| Indicator | MSC | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 60.35 | 21.27 |
| Support Level | $0.77 | N/A |
| Resistance Level | $1.31 | $2.82 |
| Average True Range (ATR) | 0.15 | 0.02 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 66.65 | 24.00 |
Studio City International Holdings Ltd is a gaming, retail, and entertainment resort located in Cotai, Macau. It operates Studio City Casino with around 250 mass-market gaming tables; including tables for VIP rolling chip operations, and 552 gaming machines. Studio City features luxury hotel rooms, diverse food and beverage establishments, and complementary retail space. In addition, the company offers non-gaming attractions, including the world's first figure-8 Ferris wheel, a deluxe nightclub and karaoke venue, a live performance arena, an outdoor and an indoor water park. Geographically, the company derives the majority of its revenue from the Macau region.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.